List view / Grid view
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
Researchers have found that mitochondrial dysfunction in the blood-brain barrier may drive neuropsychiatric disease in 22q11.2 deletion syndrome – and that a cholesterol drug could restore barrier function and ease symptoms.
A new study shows high triglyceride levels directly cause abdominal aortic aneurysms – highlighting triglyceride-lowering therapies as a potential new treatment.
Researchers at UNSW Sydney have unveiled a next-generation CRISPR tool that could lead to safer treatments for genetic disorders, including Sickle Cell.
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…
An existing asthma drug has been shown to almost completely prevent life-threatening allergic reactions to food in mice, after researchers found a previously unknown genetic pathway linked to anaphylaxis.
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant “zombie” tumour cells – which could allow for the development of more durable treatments.
New research from Harvard Medical School shows that natural lithium deficiency in the brain may be a key early factor driving Alzheimer’s disease – which allow for the development of new approaches to preventing and reversing cognitive decline.
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
Researchers at Mount Sinai have mapped how the 5-HT1A serotonin receptor controls brain signalling – finding a hidden lipid ‘co-pilot’ that could lead to the development of more targeted antidepressants.
Scientists at Ghent University have discovered that a simple combination of vitamin B1 and glucose could drastically improve survival in sepsis – a life-threatening condition responsible for millions of deaths each year.
Scientists have discovered that infections like COVID-19 and flu can “wake up” dormant breast cancer cells – triggering new tumour growth in the lungs.
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
